Hydrochlorothiazide

Hydrochlorothiazide
Product Description

Hydrochlorothiazide

Therapeutic Area: Cardiovascular system

  • EU DMF available
  • US DMF no. 17599 available
  • Japanese DMF available 
  • CEP available
 
DISCLAIMER

Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s).

Products protected by patents in force in Poland are developed solely for the purpose of Regulatory Submissions.

Read more Show less

Polpharma S.A.

  • PL
  • 2015
    On CPHI since
  • 4
    Certificates
  • 5000+
    Employees
Company types
CMO/CDMO
Contract Service
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Pharmaceutical company
View company profile
Categories
more categories Show less
Specifications
  • CAS Registry Number
    58-93-5
  • Details
    Therapeutic Area: Cardiovascular system
    • EU DMF available
    • US DMF no. 17599 available
    • Japanese DMF available 
    • CEP available
    Indication: Hydrochlorothiazide is a diuretic drug of the thiazide class that acts by inhibiting the kidneys' ability to retain water. This reduces the volume of the blood, decreasing blood return to the heart and thus cardiac output and, by other mechanisms, is believed to lower peripheral vascular resistance

    DISCLAIMER

    Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s).

    Products protected by patents in force in Poland are developed solely for the purpose of Regulatory Submissions.

  • Selling Points
    ✔️ HP API (OEL up to 10 ng/m3)
    ✔️ EU manufacturing site
    ✔️ US FDA-approved
    ✔️ 70 years of experience in small molecules
    ✔️ cGMP manufacturing
    ✔️ Highest quality standards
    ✔️ Research, Development, and Commercial Manufacturing
    ✔️ World-class regulatory support
    ✔️ Smooth and transparent cooperation
  • Supplied from
    Poland
  • Measured In
    gram; kilogram
More specifications Fewer specifications
Sales Markets
Show more Show less

Polpharma S.A.

  • PL
  • 2015
    On CPHI since
  • 4
    Certificates
  • 5000+
    Employees
Company types
CMO/CDMO
Contract Service
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Pharmaceutical company
View company profile

More Products from Polpharma S.A. (4)

  • Ticagrelor

    Product Ticagrelor

    Ticagrelor 

    form II 

    Own process patent to free from nitrosamines 

    CEP, 
    US DMF, 
    EU DMF,  
    Korean DMF, 
    Canadian DMF, 
    Cadifa

    DISCLAIMER

    Products protected b...
  • Alendronate sodium

    Product Alendronate sodium

    Alendronate Sodium
    Trihydrate

    > No risk of presence of nitrosamines
    > Long experience with commercial manufacturing
    > In-house production of the whole product family (Risedronate, Alendronate, Ibandronate)

    CEP, 
    US D...
  • Pentoxifylline

    Product Pentoxifylline

    Pentoxifylline
    Form I

    > Very long production experience
    > Tailor made PSD

    CEP, 
    US DMF, 
    CHINESE


    This product is not offered for sale or made available in countries where it is subject to patent (SP...
  • Dapagliflozin

    Product Dapagliflozin

    Dapagliflozin
    amorphous & propanediol

    > Cryogenic process
    > Green Chemistry

    EU DMF
    US DMF
    Korean DMF
    Canadian DMF 
    DISCLAIMER

    Products protected by valid patents are not offer...

Polpharma S.A. resources (2)

  • CPHI Barcelona 2023: Tackling the Pharma Talent Precipice – Part 2

    News CPHI Barcelona 2023: Tackling the Pharma Talent Precipice – Part 2

    This year at CPHI Barcelona (24–26 October, 2023) we sat down with C-suite executives and HR professionals to discuss the looming talent crisis in the pharmaceutical industry. With hybrid working persisting post-pandemic and a growing skills gap, how can the pharmaceutical supply chain adjust to a changing labour force? 
    15 Nov 2023
  • API Product List 2024

    Brochure API Product List 2024

    We manufacture our products by following our customers' and health authorities' most stringent requirements. DMF documentation for all our products is prepared in accordance with the latest requirements of EDQM (CEP), ICH (EuDMF, CTD), and FDA (US DMF). Material and product testing is performed in line with the European and United States Pharmacopeias.